Grifols/GRFS
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Grifols
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.
Ticker
GRFS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Barcelona, Spain
Employees
23,744
Website
www.grifols.com
Grifols Metrics
BasicAdvanced
$6.2B
Market cap
73.28
P/E ratio
$0.10
EPS
0.57
Beta
-
Dividend rate
Price and volume
Market cap
$6.2B
Beta
0.57
52-week high
$12.15
52-week low
$5.30
Average daily volume
39
Financial strength
Current ratio
2.786
Quick ratio
1.292
Long term debt to equity
158.216
Total debt to equity
173.625
Enterprise value to free cash flow
52.859
Interest coverage (TTM)
1.56%
Management effectiveness
Return on assets (TTM)
0.84%
Return on equity (TTM)
0.99%
Return on investment (TTM)
1.06%
Valuation
Price to earnings (TTM)
73.278
Price to revenue (TTM)
0.865
Price to book
0.77
Growth
3-year revenue growth
7.27%
3-year earnings per share growth
-55.02%
What the Analysts think about Grifols
Analyst Ratings
Majority rating from 10 analysts.
Grifols Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
€1.8B
10.77%
Net income
€56M
-6.05%
Profit margin
3.15%
-15.32%
Grifols Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
€0.14
€0.11
€0.14
€0.07
-
Expected
€0.17
€0.22
€0.22
€0.15
€0.21
Surprise
-17.65%
-50.73%
-36.79%
-52.57%
-
Grifols News
AllArticlesVideos
![](https://cdn.snapi.dev/images/v1/e/r/press12-2508965.jpg)
The Schall Law Firm Commences Inquiry Into Allegations Against Grifols SA And Urges Affected Investors To Initiate Communication
Accesswire·17 hours ago
![](https://cdn.snapi.dev/images/v1/w/p/press18-2507330.jpg)
Probe Into Claims Against Grifols SA Initiated By The Schall Law Firm And Impacted Investors Are Encouraged To Start Contact
Accesswire·2 days ago
![](https://cdn.snapi.dev/images/v1/t/z/biotech12-2507277.jpg)
Unit of Grifols shareholder Scranton reaches debt refinancing deal
Reuters·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Grifols stock?
Grifols (GRFS) has a market cap of $6.2B as of July 04, 2024.
What is the P/E ratio for Grifols stock?
The price to earnings (P/E) ratio for Grifols (GRFS) stock is 73.28 as of July 04, 2024.
Does Grifols stock pay dividends?
No, Grifols (GRFS) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next Grifols dividend payment date?
Grifols (GRFS) stock does not pay dividends to its shareholders.
What is the beta indicator for Grifols?
Grifols (GRFS) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
![Buy or sell Grifols stock](/_next/image?url=%2Fresources%2Fimages%2Fpromo_phone.png&w=256&q=75)
Buy or sell Grifols stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.